Trevi Is the Last Cough Standing — and the Tape Is Punishing It for Exactly That
The last man standing problem
There is a version of this call that writes itself: two competitive programs in refractory chronic cough died this summer, Trevi Pharmaceuticals is now the only company with an active late-stage asset in the RCC market or anywhere else in chronic cough, and the stock should be off to the races. Jennifer Good said as much, in as many words: “With the recent competitive failures in RCC, we are alone in all 3 of our cough indications and have the potential to be a first-in-class therapy in very big markets.” — Jennifer Good, CEO · 2026-11-09
The tape disagrees. Trevi peaked at $19.50 on July 7 — almost exactly when the second of those competitor failures landed — and has fallen 30.7% since, including a 22.2% decline over the last ninety trading days into this report. That divergence is the whole story here. A field clearing out is normally a gift. When the field clears out because a mechanism class keeps failing its own placebo-controlled trials, the market starts pricing the survivor as the next candidate for the same fate rather than as the beneficiary.
Management knows which version of the story it is fighting. Good spent an unusual amount of her prepared remarks on the failure of GSK's camlipixant program and a second, unnamed peripheral-only competitor, arguing that peripheral mechanism alone cannot handle the heterogeneity of cough triggers, while Haduvio's dual central and peripheral action can. It is a good argument. It is also an argument the market has heard before every one of those failures.
The SSRE slip nobody wanted to explain
The more concrete news is the sample size reestimation on the LAKE trial, and it moved. On the May call, Good said of the SSRE: “We should get that in by the fourth quarter of this year.” — Jennifer Good, Chief Executive Officer · 2026-05-06 On Monday it became early in the first quarter of 2027 — a shift small in calendar terms and large in signaling terms for a stock already in a drawdown. Annabel Samimy of Stifel pressed exactly this point, and the answer had a slightly rehearsed quality: “our time lines always showed December. So when you say slip to Q1, it's early Q1. We're sort of talking about weeks here with the holiday.” — Jennifer Good, CEO · 2026-11-09
The SSRE itself is worth understanding because it is the single most informative event between now and the 2027 readouts. At 50 patients randomized, an independent unblinded team returns one of three answers with no data attached: full steam at 100 patients; a conditional power between 40% and 80%, in which case Trevi upsizes proportionally, by four to 52 patients, to a maximum of 152; or conditional power below 40%, i.e. futility. The middle band, per Good, corresponds to a drug-minus-placebo effect size in the low-20s to 30% range.
In light of the fact that the study will likely be close to fully enrolled and there are no competitive programs left, we would plan to finish enrollment based on the original sample size of 100 and look at the data.
That sentence is the tell. In a world with live competitors, a futility signal ends a program. In this world, it just means you finish the trial you already paid for and read it out anyway. Jim Cassella was explicit that conditional power is calculated on the 54mg twice-daily arm alone and that the company deliberately learns nothing else — "We have no read on what the issues are or what may be driving any kind of an upsize." The blinding is sound science and terrible for suspense.
ILD: the adaptive design quietly died
The genuinely new content on this call was the non-IPF-ILD program, where a positive FDA meeting in October converted a fairly ambitious plan into a plainer one. In March, Cassella described an adaptive Phase II/III: “the idea of the adaptive design is that we were able to pick our doses, determine what our effect size is, look at the variability in this population, immediately translate that into the Phase III study.” — James Cassella, Chief Development Officer · 2026-03-17 What was actually agreed is a standalone, roughly 120-patient, 12-week fixed-dose Phase II starting in Q1 2027, with top-line data in the first half of 2028 and a single Phase III to follow on an sNDA pathway.
That is a cleaner, cheaper, slower plan — and it is a de-risking that costs a year. The scientific bet has also narrowed to a single variable: fibrotic lung disease as the common thread across more than 100 distinct non-IPF conditions, with a minimum of about 10% fibrosis as the entry floor and level of fibrosis replacing any attempt to enrich by diagnosis. Cassella's framing was careful: “The Phase II dose-ranging study is really to identify the doses, get experience in this patient population... and then design the most efficient, hopefully, and I think realistically, 1 Phase III trial.” — James Cassella, Chief Development Officer · 2026-11-09 Note what disappeared from the language: "adaptive," "interim analysis," "melding" the ILD and IPF programs. The non IPF ILD opportunity is still described as more than doubling the IPF market, but it now sits further out on the calendar than it did a quarter ago.
Cash, patents, and the quiet execution
Financially there is nothing to argue with. Trevi ended the third quarter with roughly $299 million and a runway into 2030 that funds OCEAN-1 and OCEAN-2, the RCC Phase IIb and the new ILD Phase II through top-line — but explicitly not a commercial launch or Phase III trials in RCC or non-IPF-ILD. That is a boundary worth remembering when the first approval narrative gets written.
R&D expense reached $15 million in the latest reported quarter, up 61% year over year and 52% sequentially. Operating loss widened to $21 million. The balance sheet remains essentially unlevered, but the cash runway, at 18.3 quarters, is down about 26% from its 24.7-quarter peak in the fourth quarter of 2025. Nothing alarming; simply a company converting a balance sheet into trial sites.On intellectual property, a promise was kept. In May, Good said the company had moved on to “label enablement patents... like how you dose adjust it with food or hepatic impairment.” — Jennifer Good, Chief Executive Officer · 2026-05-06 This quarter she delivered one: “we actually did get another patent issued around dosing in hepatically impaired patients in non-IPF-ILD. That would take that protection out to 2041.” — Jennifer Good, CEO · 2026-11-09 Base method-of-use patents run to 2039. For a single-asset company that intends to keep global commercial rights — "if somebody wanted to have those rights in the U.S., they'd have to buy the company" was the August 2025 formulation, and Monday's version was softer but the same — patent life is half the equity story.
What to actually watch
Farrell Simon put a number on the commercial question analysts keep circling: of the RCC population, the severe, diagnosis-over-one-year, failed-therapy segment “really narrows that market to around 1 million patients” — Farrell Simon, Chief Commercial Officer · 2026-11-09, seen primarily by pulmonologists — the same call point already touched by an unbranded campaign reaching 93% of them. That is a coherent commercial architecture built on a high unmet need that no longer has any competing sponsor.
Which returns us to the paradox. Trevi has never had a better competitive setup and has never looked worse on the tape. The OCEAN 1 and OCEAN-2 timelines were reconfirmed, not raised. The effect size debate is now entirely internal, resolved by an unblinded statistician nobody will hear from until January, and by a cough-count endpoint that has embarrassed almost everyone who has tried it. The stock is not short of catalysts; it is short of belief that the class works. That is what the next two quarters will trade on, and no amount of being alone in the field fixes it.